Friday, September 18, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Researchsemaglutidemazdutidecounterfeitschinamisinformation

Study finds counterfeit GLP-1 promotion on China's Douyin video platform

Bilibili videos scored significantly higher on DISCERN and JAMA benchmarks than Douyin's, an asymmetry absent from Western short-video studies.

PR
By Priya Raman · Science Reporter
Sep 10 20:00 ETSource: Therapeutic advances in endocrinology and metabolism

The wire

  1. 01Researchers analysed 128 videos (56 Douyin, 72 Bilibili) returned by a search for 'GLP1', scoring quality with modified DISCERN, Global Quality Score and JAMA benchmarks.
  2. 02Safety review flagged videos promoting fraudulent products co-opting GLP-1 brand names, a risk the authors tie to China's unregulated domestic supply chain ahead of a 2026 semaglutide patent cliff.
  3. 03This is a cross-sectional snapshot of platform search results, not a measure of what patients actually watch or act on.

From the source

Assessing the quality and reliability of health information on GLP-1 receptor agonists on TikTok and Bilibili: a cross-sectional analysis of the public health infodemic

Therapeutic advances in endocrinology and metabolism · 2026 · Peng G, Wang C, Zhang HW et al.

Read at pubmed.ncbi.nlm.nih.gov
Source URL https://pubmed.ncbi.nlm.nih.gov/42756349/